News » Galecto Announces Clinical Collaboration with Roche

Galecto Announces Clinical Collaboration with Roche

3 Nov, 2021 | Press Releases

Download Press Release

BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a publicly listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has entered into a clinical trial supply agreement with Roche to explore the combination of GB1211, Galecto’s oral galectin-3 inhibitor, with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) in Galecto’s planned Phase 2a trial in non-small-cell lung cancer (NSCLC).

All news articles

Eir Ventures Invests in Purpose Pharma

Hoba Therapeutics raises EUR 23 million

Eir Ventures invests in Dania Tx

Eir Ventures celebrates 3 years anniversary

Lovisa Bacekmar new Principal

Eir invests in RAPP

Eir invests in GutCRINE

Eir Ventures leads €28M investment in Scenic Biotec

Eir Ventures invests in Henlez

Eir Ventures portfolio company, Pretzel Therapeutics, announces USD 72,5m series A financing

Eir Ventures invests in Hoba Therapeutics

Eir Ventures joins oversubscribed investment round in Attgeno

Eir Ventures strengthens team – appoints three new Partners

Eir Ventures joins oversubscribed investment round in Cinclus Pharma

Eir Ventures today announced the completion of an investment in Strike Pharma

Eir Ventures announces Co-investment agreement with Copenhagen University

Eir Ventures is happy to welcome two interns

Eir Ventures expands team with new principal

Eir Ventures Closes Life Science Venture Fund at EUR122 million

Eir Ventures completes investment in ArgusEye

Eir Ventures upscales with Investment Associate

Eir Ventures’ first “seedling” Synklino ApS completes oversubscribed DKK 106 million series A round

IO Biotech, Inc. Announces Pricing of Initial Public Offering

Galecto Announces Clinical Collaboration with Roche

Eir Ventures completes investment in one-carbon Therapeutics.